• First clinical proof of concept data with lead OncoMimics™ therapeutic cancer vaccine candidate EO2401 expected in H1 2022
• New Corporate Identity and Website Launched Today

Paris, France – November 4, 2021

Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its unique ability to decode the gut microbiome’s interaction with the immune system, announces the launch of its new corporate brand and visual identity supported by a new website.

These changes reflect the significant progress that Enterome has made with its two advanced, fully owned, OncoMimics™ and EndoMimics™ pipelines of transformational medicines for cancer and immune diseases, respectively.

Enterome’s most advanced OncoMimics™ drug candidates are:

• EO2401, a therapeutic cancer vaccine candidate currently in clinical development for recurrent glioblastoma and adrenal tumors. EO2401 has already shown strong immunogenicity data in brain and adrenal cancer patients with clinical proof of concept data expected in H1 2022, and
• EO2463, a second OncoMimic cancer vaccine, in clinical development for the treatment of indolent non-Hodgkin lymphoma with clinical proof of concept data planned for H1 2023

In addition, the Company’s most advanced EndoMimics™ candidate is:

• EB1010, a new orally delivered bioactive and a potent local inducer of IL-10, which has been selected to provide improved therapeutic outcomes for patients with inflammatory bowel disease (IBD). EB1010 is expected to enter clinical trial in 2023

The Enterome name was created using a combination of the Greek prefix “ENTER”, which means ’from the gut’ and the suffix of gen’OME’. This name highlights Enterome’s world-leading ability to interrogate the collective gut microbiome genome to identify and characterize bioactive proteins and peptides as a foundation to generate novel therapeutic vaccines and biological drugs.

Enterome’s drug discovery platform leverages a unique combination of biocomputational tools and bioassays, to explore new therapeutic solutions from the world’s largest database of 20 million functionally annotated full-length gut microbiome proteins. This use of cutting-edge tools means that Enterome’s platform is more efficient than well established, labor-intensive drug discovery approaches. Enterome’s platform has already demonstrated it is highly productive and has generated multiple pipelines of transformative drug candidates, targeting a broad range of therapeutic areas.

Download the press release (.pdf format)